Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | JNJ-87890387 |
Synonyms | |
Therapy Description |
JNJ-87890387 is a bispecific antibody that targets ENPP3 on tumor cells and CD3 expressed on T-cells, which may induce cytotoxicity against tumor cells expressing ENPP3 and inhibit tumor growth (Cancer Res (2024) 84 (7_Supplement): LB122). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
JNJ-87890387 | JNJ 87890387|JNJ87890387 | CD3 Antibody 103 | JNJ-87890387 is a bispecific antibody that targets ENPP3 on tumor cells and CD3 expressed on T-cells, which may induce cytotoxicity against tumor cells expressing ENPP3 and inhibit tumor growth (Cancer Res (2024) 84 (7_Supplement): LB122). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT06178614 | Phase I | JNJ-87890387 | A Study of JNJ-87890387 for Advanced Solid Tumors | Recruiting | USA | FRA | ESP | 0 |